12 results on '"Luevano J"'
Search Results
2. PB2049: MEXICAN REGISTRY OF MYELOPROLIFERATIVE NEOPLASMS. INITIAL REPORT
- Author
-
De La Peña Celaya, J. A., primary, Tapia Enriquez, A. L., additional, Paredes Lozano, E. P., additional, Bates Martin, R., additional, Villela Peña, A., additional, Teomitzi Sanchez, O., additional, Ovilla Martinez, R., additional, Ramirez Muñiz, N., additional, Cuevas Juarez, A., additional, Lopez Flores, A. M., additional, Medina Coral, J. E., additional, Garcia Camacho, A. S., additional, Garcia Castillo, C., additional, Bahena Garcia, M. M., additional, Romero Rodelo, H., additional, Aguilar Luevano, J., additional, Baez Islas, P. E., additional, Alvarez Vera, J. L., additional, Perez Zuñiga, J. M., additional, Hernandez Ruiz, E., additional, Arana Luna, L. L., additional, Espitia Rios, M. E., additional, Montoya Jimenez, L., additional, and Alvarado Ibarra, M., additional
- Published
- 2022
- Full Text
- View/download PDF
3. Gastric transposition after esophago-coloplasty failure by the graft necrosis in the surgical management of the long gap esophageal atresia type I
- Author
-
Nari, G. A., García-Luevano, J., Guerrero-Huerta, C., and Barragán-Reveles, R.
- Published
- 2010
4. The pro-apoptotic role of autophagy in breast cancer
- Author
-
Suman, S, primary, Das, T P, additional, Reddy, R, additional, Nyakeriga, A M, additional, Luevano, J E, additional, Konwar, D, additional, Pahari, P, additional, and Damodaran, C, additional
- Published
- 2014
- Full Text
- View/download PDF
5. Gastric transposition after esophago-coloplasty failure by the graft necrosis in the surgical management of the long gap esophageal atresia type I
- Author
-
Nari, G. A., primary, García-Luevano, J., additional, Guerrero-Huerta, C., additional, and Barragán-Reveles, R., additional
- Published
- 2010
- Full Text
- View/download PDF
6. Metabolomics of head and neck cancer in biofluids: an integrative systematic review.
- Author
-
Chuchueva N, Carta F, Nguyen HN, Luevano J, Lewis IA, Rios-Castillo I, Fanos V, King E, Swistushkin V, Reshetov I, Rusetsky Y, Shestakova K, Moskaleva N, Mariani C, Castillo-Carniglia A, Grapov D, Fahrmann J, La Frano MR, Puxeddu R, Appolonova SA, and Brito A
- Subjects
- Humans, Alanine, Glucose, Metabolomics, Body Fluids, Head and Neck Neoplasms diagnosis
- Abstract
Introduction: Head and neck cancer (HNC) is the fifth most common cancer globally. Diagnosis at early stages are critical to reduce mortality and improve functional and esthetic outcomes associated with HNC. Metabolomics is a promising approach for discovery of biomarkers and metabolic pathways for risk assessment and early detection of HNC., Objectives: To summarize and consolidate the available evidence on metabolomics and HNC in plasma/serum, saliva, and urine., Methods: A systematic search of experimental research was executed using PubMed and Web of Science. Available data on areas under the curve was extracted. Metabolic pathway enrichment analysis were performed to identify metabolic pathways altered in HNC. Fifty-four studies were eligible for data extraction (33 performed in plasma/serum, 15 in saliva and 6 in urine)., Results: Metabolites with high discriminatory performance for detection of HNC included single metabolites and combination panels of several lysoPCs, pyroglutamate, glutamic acid, glucose, tartronic acid, arachidonic acid, norvaline, linoleic acid, propionate, acetone, acetate, choline, glutamate and others. The glucose-alanine cycle and the urea cycle were the most altered pathways in HNC, among other pathways (i.e. gluconeogenesis, glycine and serine metabolism, alanine metabolism, etc.). Specific metabolites that can potentially serve as complementary less- or non-invasive biomarkers, as well as metabolic pathways integrating the data from the available studies, are presented., Conclusion: The present work highlights utility of metabolite-based biomarkers for risk assessment, early detection, and prognostication of HNC, as well as facilitates incorporation of available metabolomics studies into multi-omics data integration and big data analytics for personalized health., (© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
- Published
- 2023
- Full Text
- View/download PDF
7. Rare Presentation of Postpericardiotomy Syndrome After Left Atrial Myxoma Removal.
- Author
-
Feng J, Appareddy NS, Gibran Y, Garza A, Luevano J, and Garcia G
- Subjects
- Female, Humans, Aged, Postpericardiotomy Syndrome etiology, Postpericardiotomy Syndrome complications, Postoperative Complications diagnosis, Postoperative Complications etiology, Cardiac Surgical Procedures, Heart Neoplasms complications, Heart Neoplasms diagnosis, Heart Neoplasms surgery, Myxoma complications, Myxoma diagnosis, Myxoma surgery
- Abstract
Postpericardiotomy syndrome (PPS) is a known complication of cardiac valve surgery, but it has not been commonly reported as a postoperative complication of cardiac myxoma removal. A 78-year-old female with hypertension and atrial fibrillation presenting with angina was found to have a large left atrial myxoma (7.5 cm × 4.4 cm). The myxoma was resected; however, 1-week postoperation hemoglobin and blood pressure decreased with elevated erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP). Limited transthoracic echocardiogram (TTE) showed moderate pericardial effusion, confirming the diagnosis of PPS. This case highlights the importance of monitoring patients postremoval of myxoma for symptoms of PPS., Competing Interests: Declaration of Conflicting InterestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
- Published
- 2023
- Full Text
- View/download PDF
8. Predictive Gestational Diabetes Biomarkers With Sustained Alterations Throughout Pregnancy.
- Author
-
Heath H, Luevano J, Johnson CM, Phelan S, and La Frano MR
- Abstract
Gestational diabetes mellitus (GDM) results in an increased risk of pre- and postpartum health complications for both mother and child. Metabolomics analysis can potentially identify predictive biomarkers and provide insight into metabolic alterations associated with GDM pathogenesis and progression, but few metabolomics studies investigate alterations observed across the first and third trimester. We hypothesize that metabolites altered in first-trimester GDM that remain altered in late pregnancy may best inform interventions. Metabolomic studies comparing plasma and serum metabolite alterations in GDM vs non-GDM pregnancies were retrieved by searching PubMed, Medline, and CINAHL Plus databases. The present scoping review summarizes the metabolites found to be consistently altered throughout the course of GDM and proposes mechanisms that explain how these metabolic perturbations relate to GDM development and progression. Metabolites involved in fatty acid metabolism, reductive carboxylation, branched-chain amino acid metabolism, cell membrane lipid metabolism, purine degradation, and the gut microbiome were found to be altered throughout GDM pregnancies, with many of these pathways showing mechanistic links to insulin resistance, inflammation, and impaired cell signaling. Future studies are required to investigate if normalization of these perturbed pathways can be the targets of interventions., (© The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society.)
- Published
- 2022
- Full Text
- View/download PDF
9. Mexican Consensus on Hodgkin's Lymphoma.
- Author
-
Álvarez-Vera JL, Aguilar-Luevano J, Alcívar-Cedeño LM, Arana-Luna LL, Arteaga-Ortiz L, Báez-Islas PE, Carolina-Reynoso A, Cesarman-Maus G, Peña-Celaya JA, Espitia-Ríos ME, Fermín-Caminero DJ, Flores-Patricio W, García-Camacho AS, Guzmán-Mora PG, Hernández-Colín AK, Hernández-Ruiz E, Herrera-Olivares W, Jacobo-Medrano E, Loera-Fragoso SJ, Macías-Flores JP, Martínez-Ramírez MA, Medina-Guzmán L, Milán-Salvatierra AI, Montoya-Jiménez L, Morales-Adrián JJ, Mujica-Martínez A, Nava-Villegas L, Orellana-Garibay JJ, Palma-Moreno OG, Pérez-Zúñiga JM, Pérez-Gómez KD, Pichardo-Cepín YM, Rojas-Castillejos F, Romero-Martínez E, Romero-Rodelo H, Segura-García A, Silva-Vera K, Tapía-Enríquez AL, Teomitzi-Sánchez Ó, Tepepa-Flores F, Vilchis-González SP, Villela-Peña A, Guerra-Alarcón LV, Reséndiz-Olea R, Banda-García L, Paredes-Lozano EP, and Alvarado-Ibarra M
- Subjects
- Age Distribution, Algorithms, Antineoplastic Agents therapeutic use, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Gene Expression, Humans, Mexico, Neoplasm Staging, Positron Emission Tomography Computed Tomography, Consensus, Hodgkin Disease drug therapy, Hodgkin Disease epidemiology, Hodgkin Disease genetics, Hodgkin Disease pathology, Reed-Sternberg Cells pathology
- Abstract
Hodgkin's lymphoma is due to the clonal transformation of cells originating from B lymphocytes, generating the pathognomonic binucleate Reed-Sternberg cells. Hodgkin's lymphoma is a B cell disease with a bimodal distribution, with higher incidence in adolescence and the third decade of life, showing a second peak in people over 55 years of age. Classic Hodgkin lymphoma cells routinely undergo gene expression reprogramming, as they lose the expression of most of the typical B-cell genes and acquire the expression of multiple genes that are typical of other types of cells in the immune system. The treatment algorithm will depend on whether it is classic or predominantly lymphocytic HL, if it is early stage with unfavorable prognostic markers or not, the initial management regimen, and whether there is bulky disease, among the most relevant variables., (Copyright: © 2021 Permanyer.)
- Published
- 2021
- Full Text
- View/download PDF
10. Mexican Concensus of Multiple Myeloma.
- Author
-
de la Peña-Celaya JA, Aguilar-Luevano J, Alcivar-Cedeño LM, Álvarez-Vera JL, Anaya-Cuellar I, Añorve-Hernández E, Arana-Luna LL, Arteaga-Ortíz L, Báez-Islas PE, Banda-García LI, Bates-Martín RA, Campa-Monroy DI, Cardiel-Silva M, Castillo-Salas ÁJ, Cota-Rangel X, Díaz-Vargas G, Espitia-Ríos ME, Estrada-Domínguez P, Fermín-Caminero D, García-Camacho A, García-Castillo C, Garzón-Velásquez KB, Gil-Rondero C, Guerra-Alarcón LV, Hernández-Colín AK, Hernández-Ruiz E, Hernández-Alcántara AE, Hernández-Cervantes SA, Herrera-Olivares W, Ignacio-Ibarra G, Inclán-Alarcón SI, Leyto-Cruz F, Macías-Flores JP, Vega AM, Martínez-Ramírez MA, Martínez-Coronel J, Medina-Coral JE, Meza-Dávalos L, Montoya-Jiménez L, Morales-Hernández A, Morales-López E, Morales-Adrián JJ, Azcué MM, Mújica-Martínez A, Murillo-Cruz JL, Nájera-Martínez J, Narváez-Sarmiento IM, Nava-Villegas L, Nava-Alpide MA, Orellana Garibay JJ, Palafox-Zaldívar MT, Palma-Moreno OG, Paredes-Lozano EP, Pedraza-Colín ML, Pérez-Zúñiga JM, Pérez-Lizardi AB, Rojas-Castillejos F, Romero-Martínez E, Romero-Rodelo H, Ruiz-Contreras J, Saavedra-González A, Saucedo-Montes E, Silva-Michel LG, Silva-Vera K, Teomitzi-Sánchez Ó, Tepepa-Flores F, Ventura-Enríquez Y, Villela-Peña A, Vilchis-González SP, Zapata-Canto N, Zárate-Rodríguez PA, and Alvarado-Ibarra M
- Subjects
- Algorithms, Humans, Mexico, Multiple Myeloma complications, Multiple Myeloma diagnosis, Multiple Myeloma therapy
- Abstract
To identify this increasingly common pathology, known as multiple myeloma (MM), it is necessary to refer to the specific factors that characterize it; to this end, the classic criteria known as CRAB (hyperkalemia, renal failure, anemia, and lytic lesions) are available, in which renal failure is one of the most frequent complications. Recently, three indisputable biomarkers have been described for the diagnostic support for MM, which are: more than 10% of clonal plasma cells in bone marrow or, a biopsy that corroborates the presence of a plasmacytoma, light chain ratio ≥ 100 mg/dL and more than one focal lesion on magnetic resonance imaging. A differential diagnosis for plasma cell leukemia, solitary bone plasmacytoma, and extramedullary plasmacytoma should always be considered. Being this an incurable disease, a lot of research has been done regarding its therapeutic management, whose main objective is the disappearance of plasma cells and the patient clinical improvement. Melphalan was the first drug that showed a benefit in 1958 and afterward, with the addition of a steroid as a second drug, it was possible to improve response rates. Subsequently, different molecules were studied, forming multiple combinations, and achieving better rates of overall survival and progression-free survival. Years later, with the arrival of proteasome inhibitors such as bortezomib, and immunomodulators such as thalidomide and lenalidomide, an important turnaround in the disease has been seen, as deeper responses, more prolonged remissions, and improvement in the quality of life of patients have been achieved. This consensus has the purpose of integrating a group of Mexican specialists and promoting the updating of this pathology., (Copyright: © 2020 Permanyer.)
- Published
- 2020
- Full Text
- View/download PDF
11. A review of molecular events of cadmium-induced carcinogenesis.
- Author
-
Luevano J and Damodaran C
- Subjects
- Animals, Autophagy drug effects, Carcinogenesis genetics, Cell Proliferation drug effects, DNA Repair drug effects, Epigenesis, Genetic drug effects, Humans, Cadmium toxicity, Carcinogenesis chemically induced, Carcinogens, Environmental toxicity
- Abstract
Cadmium (Cd) is a toxic, heavy industrial metal that poses serious environmental health hazards to both humans and wildlife. Recently, Cd and Cd-containing compounds have been classified as known human carcinogens, and epidemiological data show causal associations with prostate, breast, and lung cancer. The molecular mechanisms involved in Cd-induced carcinogenesis are poorly understood and are only now beginning to be elucidated. The effects of chronic exposure to Cd have recently attracted great interest due to the development of malignancies in Cd-induced tumorigenesis in animals models. Briefly, various in vitro studies demonstrate that Cd can act as a mitogen, can stimulate cell proliferation and inhibit apoptosis and DNA repair, and can induce carcinogenesis in several mammalian tissues and organs. Thus, the various mechanisms involved in chronic Cd exposure and malignant transformations warrant further investigation. In this review, we focus on recent evidence of various leading general and tissue-specific molecular mechanisms that follow chronic exposure to Cd in prostate-, breast-, and lung-transformed malignancies. In addition, in this review, we consider less defined mechanisms such as epigenetic modification and autophagy, which are thought to play a role in the development of Cd-induced malignant transformation.
- Published
- 2014
- Full Text
- View/download PDF
12. Gastric transposition after esophago-colonoplasty failure because of graft necrosis during the treatment of long-gap esophageal atresia type I.
- Author
-
Nari GA, García Luevano J, Guerrero Huerta C, and Barragán Reveles R
- Subjects
- Anastomosis, Surgical, Esophageal Atresia classification, Esophageal Fistula etiology, Esophageal Fistula surgery, Esophagostomy, Female, Gastric Fistula etiology, Gastric Fistula surgery, Gastrostomy, Graft Rejection, Humans, Infant, Newborn, Necrosis, Postoperative Complications etiology, Postoperative Complications surgery, Reoperation, Sutures adverse effects, Colon transplantation, Esophageal Atresia surgery, Esophagoplasty methods, Stomach surgery, Transplantation, Heterotopic methods
- Published
- 2010
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.